Main Article Content
Sofosbuvir/ledipasvir, COVID-19, efficacy, safety
Background: There is no study regarding the use of SOF/LDP in treatment of COVID-19.
Objectives: In this study, the efficacy and safety of SOF/LDP were assessed in treatment of patients with mild to moderate COVID-19.
Methods: Among an open-label randomized clinical trial, 82 patients with mild to moderated COVID-19 were assigned to receive either SOF/LDP 400/100 mg daily plus the standard of care (SOF/LDP group, n=42) or the standard of care alone (control group, n=40) for 10 days. Time to clinical response, rate of clinical response, duration of hospital and ICU stay and 14-day mortality were assessed.
Results: Clinical response occurred in 91.46% of patients. Although rates of clinical response were comparable between the groups but it occurred faster in the SOF/LDP group than the control group (2 vs. 4 days respectively, P= 0.02). Supportive cares were provided in the medical wards for most patients but 17.07% of patients were transferred to ICU during the hospitalization course. However, durations of hospital and ICU stay were comparable between the groups. 14-day mortality rate was 7.14% and 7.5% in the SOF/ LDP and control groups respectively. No adverse effects leading to drug discontinuation occurred. Gastrointestinal events (nausea, vomiting and diarrhea) were the most common side effects (15.85%).
Conclusion: Added to the standard of care, SOF/LDP accelerated time to the clinical response. However, rate of clinical response, duration of hospital and ICU stay and 14-day mortality were not different. No significant adverse event was detected. More randomized clinical trials with larger sample sizes are needed to confirm the efficacy and safety of SOF/LDP in the treatment of COVID-19.
2. Chan J.F.-W, Yuan S, Kok K.-H, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020; 395(10223):514-523.
3. Huang C, Wang Y, Li X, Ren L, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet;395(10223):497-506.
4. Jin Y-H, Cai L, Cheng Z-S, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res 2020;7:4.
5. Shi Y, Wang Y, Shao C, et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ 2020; 27(5): 1451–1454.
6. Su S, Wong G, Shi W, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol 2016;24(6):490-502.
7. Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003;348(20):1953-66.
8. Zaki AM, Van Boheemen S, Bestebroer TM, et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012;367(19):1814-20.
9. Hilgenfeld R, Peiris M. From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses. Antiviral Res 2013;100(1):286-95.
10. Chen YW, Yiu C-PB, Wong K-Y. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. F1000 Research 2020;9:129.
11. Schinazi RF, Shi J, Whitaker T. Sofosbuvir (Sovaldi): The First-in-Class HCV NS5B Nucleotide Polymerase Inhibitor. Innovative Drug Synthesis. 2016:61-80.
12. Zuccaro V, Lombardi A, Asperges E, et al. PK/PD and antiviral activity of anti-HCV therapy: is there still a role in the choice of treatment? Expert Opin Drug Metab Toxicol 2020 ;16(2):97-101.
13. Elfiky AA, Mahdy SM, Elshemey WM. Quantitative structure‐activity relationship and molecular docking revealed a potency of anti‐hepatitis C virus drugs against human corona viruses. J Med Virol 2017;89(6):1040-1047.
14. Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci 2020;248:117477.
15. Elfiky AA. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci 2020;253:117592.
16. Sadeghi A, Asgari AA, Norouzi A et al. Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial. J Antimicrob Chemother 2020 Aug 19.
17. Kasgari HA, Moradi S, Shabani AM et al. Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a singlecentre, randomized controlled trial. J Antimicrob Chemother 2020 Nov 1;75(11):3373-3378.
18. Eslami G, Mousaviasl S, Radmanesh E et al. The impact of sofosbuvir/ daclatasvir or ribavirin in patients with severe COVID-19. J Antimicrob Chemother 2020 Aug 19.
19. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020 24. doi: 10.1001/jama.2020.2648.
20. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 2020;109:102433.
21. Simmons B , Wentzel H , Mobarak S, et al. Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis. J Antimicrob Chemother 2020 Oct 16.
22. Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020;382(19):1787-1799.
23. Tang W, Cao Z, Han M, Wang Z, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ 2020; 369: m1849.
24. Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020;105949.
25. Mehra MR, Desai SS, Ruschitzka F, et al. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet 2020.
26. Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state. JAMA 2020. doi: 10.1001/jama.2020.8630
27. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020; 395(10236): 1569–1578.
28. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19—Preliminary Report. N Engl J Med 2020 May 22. doi: 10.1056/NEJMc2022236
29. Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med 2020 May 27. doi: 10.1056/NEJMoa2015301
30. Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing) 2020 Mar 18. doi: 10.1016/j.eng.2020.03.007
31. Zhou Q, Wei X-S, Xiang X, et al. Interferon-a2b treatment for COVID-19. medRxiv; 2020.
32. Hung IF-N, Lung K-C, Tso EY-K, et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet 2020 May 30;395(10238):1695-1704.
33. Zhou F, Yu T, Du R, Fan G, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395(10229):1054-1062.
34. Wu C, Chen X, Cai Y, et al .Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020 Mar 13. doi: 10.1001/jamainternmed.2020.0994
35. Fedson DS. Treating influenza with statins and other immunomodulatory agents. Antiviral Res 2013;99(3):417-435.
36. Fedson DS. A practical treatment for patients with Ebola virus disease. J Infect Dis 2015;211(4):661-662.
37. Lu R, Zhao X, Li J, Niu P, et al . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020;395(10224):565-574.
38. Tikoo K, Patel G, Kumar S, et al. Tissue specific up regulation of ACE2 in rabbit model of atherosclerosis by atorvastatin: Role of epigenetic histone modifications. Biochem Pharmacol 2015;93(3):343-351.
39. Fedson DS, Opal SM, Rordam OM. Hiding in plain sight: an approach to treating patients with severe COVID-19 infection. mBio 2020;11(2):e00398-20.
40. Madjid M, Safavi-Naeini P, Solomon SD, et al. Potential effects of coronaviruses on the cardiovascular system: a review. JAMA Cardiol 2020 Mar 27. doi: 10.1001/jamacardio.2020.1286
41. Carr AC. A new clinical trial to test high-dose vitamin C in patients with COVID-19. Crit Care 2020;24:133.
42. Prajapat M, Sarma P, Shekhar N, et al. Drug targets for corona virus: A systematic review. Indian journal of pharmacology. Indian J Pharmacol 2020;52(1):56-65.
43. Dustin LB, Bartolini B, Capobianchi MR, et al. Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response to therapy. Clin Microbiol Infect 2016;22(10):826-832.
44. Sirohi D, Kuhn RJ. Zika virus structure, maturation, and receptors. J Infect Dis 2017;216(suppl_10):S935-S944.
45. Fehr AR, Perlman S. Coronaviruses: An Overview of Their Replication and Pathogenesis. Coronaviruses 2015;1282:1–23.
46. Babusis D, Curry MP, Kirby B, et al. Sofosbuvir and ribavirin liver pharmacokinetics in patients infected with hepatitis C virus. Antimicrob Agents Chemother 2018; 62(5):e02587-17.
47. Pockros PJ. Nucleoside/nucleotide analogue polymerase inhibitors in development. Clin Liver Dis 2013;17(1):105-10.
48. Lam AM, Espiritu C, Bansal S, et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother 2012;56(6):3359-68.
49. Fenaux M, Lin X, Yokokawa F, et al. Antiviral nucleotide incorporation by recombinant human mitochondrial RNA polymerase is predictive of increased in vivo mitochondrial toxicity risk. Antimicrob Agents Chemother 2016;60(12):7077-7085.
50. Thi VLD, Debing Y, Wu X, et al. Sofosbuvir inhibits hepatitis E virus replication in vitro and results in an additive effect when combined with ribavirin. Gastroenterology 2016;150(1):82-85.e4.
51. Netzler NE, Tuipulotu DE, Vasudevan SG, et al. Antiviral candidates for treating hepatitis E virus infection. Antimicrob Agents Chemother 2019;63(6):e00003-19.
52. Wang W, Hakim MS, Nair VP, et al. Distinct antiviral potency of sofosbuvir against hepatitis C and E viruses. Gastroenterology 2016;151(6):1251-1253.
53. Jiang W, Muhammad F, Ma P, et al. Sofosbuvir inhibits hepatitis A virus replication in vitro assessed by a cell-based fluorescent reporter system. Antiviral Res 2018;154:51-57.
54. Bullard-Feibelman KM, Govero J, et al. The FDA-approved drug sofosbuvir inhibits Zika virus infection. Antiviral Res 2017;137:134-140.
55. Vicenti I, Dragoni F, Giannini A, et al. Development of a Cell-Based Immunodetection Assay for Simultaneous Screening of Antiviral Compounds Inhibiting Zika and Dengue Virus Replication. SLAS Discov 2020;25(5):506-514.
56. Sacramento CQ, de Melo GR, Rocha N, et al. The clinically approved antiviral drug sofosbuvir impairs Brazilian zika virus replication. bioRxiv. 2016:061671.
57. Mumtaz N, Jimmerson LC, Bushman LR, et al. Cell-line dependent antiviral activity of sofosbuvir against Zika virus. Antiviral Res 2017;146:161-163.
58. Dragoni F, Boccuto A, Picarazzi F, et al. Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro. Antiviral Res 2020 ;175:104708.